Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis
- Authors
- Koh, Won-Jung; Lee, Seung Heon; Kang, Young Ae; Lee, Chang-Hoon; Choi, Jae Chol; Lee, Jae Ho; Jang, Seung Hun; Yoo, Kwang Ha; Jung, Ki Hwan; Kim, Ki Uk; Choi, Sang Bong; Ryu, Yon Ju; Kim, Kyung Chan; Um, Soojung; Kwon, Yong Soo; Kim, Yee Hyung; Choi, Won-Ii; Jeon, Kyeongman; Hwang, Yong Ii; Kim, Se Joong; Lee, Young Seok; Heo, Eun Young; Lee, Juhee; WoonKi, Yeo; Shim, Tae Sun; Yim, Jae-Joon
- Issue Date
- 1-10월-2013
- Publisher
- AMER THORACIC SOC
- Keywords
- levofloxacin; multidrug-resistant tuberculosis; fluoroquinolone; moxifloxacin
- Citation
- AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, v.188, no.7, pp.858 - 864
- Indexed
- SCIE
SCOPUS
- Journal Title
- AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Volume
- 188
- Number
- 7
- Start Page
- 858
- End Page
- 864
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/101913
- DOI
- 10.1164/rccm.201303-0604OC
- ISSN
- 1073-449X
- Abstract
- Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. Objectives: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. Methods: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions. Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75). Conclusions: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.